Kornimate/medical-research-clean huggingface dataset:
the efficacy and safety of chlorhexidine gluconate chip (periochip®) in therapy of symptoms in patients with peri-implantitis

Conditions: Peri-implantitis

Summary: the purpose of the study is to assess the efficacy and the safety of chlorhexidine gluconate chip (periochip®) versus placebo chip in treatment of symptoms in patients with peri-implantitis.

this is a phase 2a study assessing the safety and efficacy of chlorhexidine gluconate chip (periochip®) versus placebo chip in treatment of symptoms in patients with peri-implantitis

Eligibility criteria:
inclusion criteria: 1. signed and dated informed consent form. 2. good general health. 3. male or female patients aged \>21 years old. 4. availability for the 25 week duration of the study. 5. peri-implantitis is characterized by the presence of at least 1 implant with periodontal pockets of 6-10 mm in depth (potential target implant) demonstrating bleeding on probing without involving the apex of the implant and confirmed radiographically. 6. females of childbearing potential must be non-pregnant and non-lactating at entry and agree to use an adequate method of birth control during the study. exclusion criteria: 1. presence of oral local mechanical factors that could (in the opinion of the investigator) influence the outcome of the study. 2. presence of orthodontic appliances, or any removable appliances, that impinges on the tissues being assessed. 3. presence of soft or hard tissue tumours of the oral cavity. 4. horizontal inter implant distance ≤2 mm (if an adjacent implant exists). 5. selection of the following dental implant types as target implant/s: hydroxylapatite (ha) and/or titanium plasma-sprayed (tps). 6. history of allergy to chlorhexidine. 7. patients treated with systemic antibiotic therapy or periodontal/mechanical/local delivery therapy within 6 weeks prior to study entry and throughout the study duration. 8. patients treated with non-steroidal anti-inflammatory drugs (nsaids) within 14 days prior to entry into the study and throughout the study duration (excluding treatment of acetylsalicylic acid ≤100 mg /day). 9. patients taking phenytoin, calcium channel blockers drugs (ccbs) and/or cyclosporine, which might influence the pattern of tissue response. 10. presence of any of the following conditions: type 1 diabetes, major recurrent aphtae stomatitis, abscesses and related oral pathologies. 11. the presence of any medical or psychiatric condition or any other condition that, in the opinion of the investigator, could affect the successful participation of the patient in the study. 12. patient participates in any other clinical study 30 days prior to the start of the study and throughout the study duration. 13. patient uses chlorhexidine oral rinses/ mouthwashes on a regular basis.
multi-center medication reconciliation quality improvement study

Conditions: Adverse Drug Events; Medication Administered in Error

Summary: patients often have problems after they leave the hospital, in part because errors are made in the medications they are prescribed. the goal of this project is to develop a more accurate and safe medication prescription process when patients enter and leave the hospital and implement this process at six u.s. hospitals. the investigators will measure the success of the project and develop lessons learned so this process can be applied to other hospitals.

unintentional medication discrepancies during transitions in care (such as hospitalization and subsequent discharge) are very common and represent a major threat to patient safety. one solution to this problem is medication reconciliation. in response to joint commission requirements, most hospitals have developed medication reconciliation processes, but some have been more successful than others, and there are reports of pro-forma compliance without substantial improvements in patient safety. there is now collective experience about effective approaches to medication reconciliation, but these have yet to be consolidated, evaluated rigorously, and disseminated effectively. this project's findings should provide valuable lessons to all hospitals regarding the best ways to design and implement medication reconciliation interventions to improve medication safety during transitions in care. specific aims: aim 1: develop a toolkit consolidating the best practice recommendations for medication reconciliation aim 2: conduct a multi-center mentored quality improvement project in which each site adapts the tools for its own environment and implements them aim 3: assess the effects of a mentored medication reconciliation quality improvement intervention on unintentional medication discrepancies with potential for patient harm aim 4: conduct rigorous program evaluation to determine the most important components of a medication reconciliation program and how best to implement it

Eligibility criteria:
inclusion criteria: * age 18 and over * admitted to inpatient medical or surgical services exclusion criteria: * vulnerable populations (pregnant women, prisoners, institutionalized individuals) * under 18 years hospital staff subjects: * personnel directly involved in the medication reconciliation process, which depending on the site might include residents, physician assistants, inpatient attending physicians, nurses, pharmacists, and pharmacy technicians.

Keywords: adverse drug events
prehabilitation physical activity in persons with osteoarthritis

Conditions: Osteoarthritis

Summary: knee joint osteoarthritis (oa) reduces functional mobility and performance of daily tasks such as rising from a chair. therefore interventions aimed at improving muscle strength and sit-to-stand task performance are very important for these patients. the effect of exercise programs, including home exercise programs (hep), on muscle strength, joint pain and function is well known and widely researched, yet not many studies have investigated the effect of an hep on electromyographic activity (emg) of muscles when performing everyday tasks, such as rising from and sitting on a chair. the aim of this study was to investigate effect of prehabilitation in women with severe knee joint oa scheduled for knee joint arthroplasty (tka).


Eligibility criteria:
inclusion criteria: * for oa patients: patients with severe knee joint oa undergoing unilateral total knee arthroplasty (tka) * for controls: pain of joints more than 20/100 mm by vas exclusion criteria: for both groups: * previous total joint arthroplasty of lower limbs * other musculoskeletal, neurological and cardiovascular diseases * any diseases affecting balance and coordination.
a study of different doses of sitagliptin (mk-0431) in participants with type 2 diabetes mellitus (mk-0431-014)

Conditions: Type II Diabetes Mellitus

Summary: a study of different doses of mk-0431 in participants with type 2 diabetes mellitus. there have been 3 extensions to the base study (extension 1: up to week 52, extension 2: up to week 106, and extension 3: up to week 158). the primary hypothesis for the study is that in participants with type 2 diabetes who have inadequate glycemic control, after 12 weeks of treatment, a dose-response will be seen across once-daily doses of mk-0431 in lowering hemoglobin a1c (hba1c).


Eligibility criteria:
inclusion criteria: * men and non-pregnant women * fasting plasma glucose \>= 130 mg/dl * hba1c \>=6.5% and \>10.0% exclusion criteria: * you have a history of type i diabetes * you are on a weight loss program with ongoing weight loss or taking weight loss medication * you have had surgery within 30 days * you hvae hepatitis b or c.
effects of abdominal muscle activation training, using pressure biofeedback in comparison with surface electromyography

Conditions: Low Back Pain

Summary: this study is a randomized control trial and the purpose of this study to determine the effects of abdominal muscle activation training on non-specific low back pain; using pressure biofeedback in comparison with surface electromyography biofeedback: a randomized control trial.

the purpose of this study is to determine the effects of abdominal muscle activation training, using pressure biofeedback in comparison with surface electromyography biofeedback, in management of non-specific low back pain: a randomized control trial. pain and disability are the primary outcomes which will be determined using: 1. numeric pain rating scale (nprs) 2. oswestry disability index (odi) data will be taken before and after the intervention protocol for each participant. data collection procedure: participants of interest would be approached and explained about the research. informed written consent will be taken. pre and post intervention scores will be recorded.

Eligibility criteria:
inclusion criteria: * age (adults 19 - 44 years) * non-specific lbp with nprs \> 3 * negative slr test in prone and supine * painless extremity movement and activity * manual muscle testing of abdominal muscles between grade 2 - 4 * sedentary individuals (no exercise plan followed in last 3 months) exclusion criteria: * history of any spinal surgery * degenerative disc disorder, facet joint syndrome, spinal stenosis, myelopathy, lumbar syringomyelia * sensory disturbances due to neurological causes, lumbar radiculopathy, fibromyalgia, myofascial pain syndrome * sacroiliac joint dysfunction * pregnancy * medical conditions; hypertension, diabetes mellites * work disability greater than 6 months * not able to attend regular therapy appointments
enhancing group lifestyle intervention for depression with self-tracking tools

Conditions: Depression

Summary: this study will be a randomized controlled trial on the effects of group-based lm as an intervention for depression. prior to all study procedures, an online informed consent (with phone support) will be obtained from potential participants. around 90 eligible participants will be randomly assigned to either the lm intervention with self-tracking tools (lm/s), pure lm intervention (lm), or care-as-usual (cau) control group in a ratio of 1:1:1. the randomization will be performed by an independent assessor using a computer-generated list of numbers. in order to obtain unbiased data with respect to the participants' attitudes and behaviors, incomplete disclosure will be used to withhold the self-tracking component in this trial. participants in the two lm groups will receive six weekly group lifestyle modification sessions (\~2 hours each) at the chinese university of hong kong (an online approach will be adopted if face-to-face sessions are not possible due to covid-19). the group treatment will primarily be delivered by clinical psychology trainees under the supervision of a clinical psychologist and other healthcare professionals such as a dietitian and a fitness trainer. the cau group will continue receiving the routine care as usual and be given a smartphone-based lm intervention after the completion of follow-up assessments. both the treatment groups and control group will complete a set of online questionnaires before the treatment commences, immediately after treatment, and 12 weeks after the treatment sessions are completed. in addition, participants in the lm/s group will complete a set of self-developed survey questions related to lifestyle and mood on a daily basis.


Eligibility criteria:
inclusion criteria: 1. hong kong residents aged ≥ 18 years 2. cantonese language fluency and readability 3. a patient health questionnaire 9 items (phq-9) score of at least 10, indicating a moderate level of depression 4. possession of an internet-enabled mobile device (ios or android operating system) 5. willingness to provide informed consent and comply with the trial protocol exclusion criteria: 1. current serious suicidal risk (non-fleeting intent or plan) as assessed by a phq-9 item 9 score \> 2 (referral information to professional mental health services will be provided) 2. any medical or neurocognitive disorder(s) that makes participation unsuitable based on the team's clinical experience or interferes with adherence to the lifestyle modification (e.g., where exercise or a change in diet are not recommended by physicians) 3. current involvement in lifestyle changes supervised by professionals 4. unstable medication or current participation in any psychotherapy for depression 5. pregnancy 6. hospitalization 7. current participation in any other trial(s)

Keywords: lifestyle medicine depression
a rehabilitation program based on daily activities in patients with cerebrovascular accident

Conditions: Stroke

Summary: mixed qualitative and quantitative study, in two phases: creation of a self-rehabilitation program based on people's daily living activities and designed with and for them. randomized controlled study to explore whether there is a potential benefit for patients with chronic stroke to use a self-rehabilitation program.

in france, stroke affects nearly 150,000 people per year and is therefore a major problem public health in france but also in europe . with improved support treatment, the mortality rate decreases, but the sequelae, linked to the consequences of the stroke, remain numerous . more than 88% of stroke victims return at home upon discharge from hospital rehabilitation. however more and more people experience difficulties as a result of this return. hospital discharge entails an imbalance between the period of hospitalization and place of residence in terms of the frequency and intensity of rehabilitation. in fact, the person benefits from rehabilitation during his hospitalization daily. after returning home, the person no longer benefits only 1 to 2 rehabilitation sessions per week, sometimes less . in view of these different elements, the investigators issue the assumption that making available to people avc a self-rehabilitation program designed with and for them and centered on the meaningful occupations of the person will allow an increase in their occupational performance in their life activities daily. the aim of this study is to create a self-rehabilitation program based on people's daily living activities and designed with and for them and to evaluate the benefits of this program with a randomized controlled study.

Eligibility criteria:
inclusion criteria: * having had a stroke ischemic or hemorrhagic for more than 6 months before inclusion in the study. * having had a single cerebral hemispheric lesion * patient informed and having signed consent exclusion criteria: -patient under guardianship or curatorship * pregnant or breastfeeding women * cognitive impairment defined by bdae \<3 * previous operation of the paretic limb at course of the last 6 months at inclusion * total absence of motor skills in the upper limb hemiplegic

Keywords: stroke self-rehabilitation program
l-carnitine and metformin in obese pcos women.

Conditions: PCOS

Summary: l-carnitine and plus metformin in clomiphene-resistant obese pcos women, reproductive and metabolic effect: a randomized clinical trial

the trial aims to compare l-carnitine and plus metformin in clomiphene-resistant obese pcos women with placebo to state the reproductive and metabolic effects in form of pregnancy and insulin resistance parameters and lipid metabolism.

Eligibility criteria:
inclusion criteria: * pco * obese * ifertile exclusion criteria: * no medical disorders * no hormonal treatment in the previous 3 months
exercise effects on sarco-osteopenia in older men

Conditions: Sarcopenia; Osteopenia

Summary: the study determined the effects of predominately resistance type exercise in combination with protein supplements on parameters of sarcopenia and osteopenia (sarco-osteopenia) in older, community dwelling men with sarcopenia and -osteopenia over 18 months.


Eligibility criteria:
inclusion criteria: * sarcopenia according to baumgartner et al.(smi: \> -2 sd\* t-score) * osteopenia at the lumbar spine or hip according to who (\> -1 sd t-score) * community dwelling people * able to transfer to our lab exclusion criteria: * secondary osteoporosis * history of hip fracture * medication/diseases that relevantly affect muscle/bone metabolism (last 2 years) * alcohol abuses of more than 60 g/d ethanol * cardio-vascular diseases that prevent exercise * very low physical capacity that prevent exercise in a group setting sd: standard deviation

Keywords: sarcopenia osteopenia older men community dwelling physical functioning
aminolaevulinic acid photodynamic therapy for hpv+ low grade cervical intraepithelial neoplasia (lsil;cin1)

Conditions: Cervical Intraepithelial Neoplasia; Low-Grade Squamous Intraepithelial Lesions; Papillomavirus Infections

Summary: this trial will study the effectiveness of photodynamic therapy with aminolaevulinic acid for the treatment of patients with hpv+ low grade cervical intraepithelial neoplasia (lsil;cin1).


Eligibility criteria:
inclusion criteria: * premenopausal women, 25-50 years of age * diagnosed with lsil/cin1 by local pathology (biopsy) and high-risk hpv positive by hc2 assay within the last 3 months * satisfactory colposcopy examination (visibility of entire transformation zone and entire lesion margin ) * meet the following conditions: pregnancy test negative; no pregnancy plan during the trial; no sexuality or reliable contraceptive measures taken since last menstruation to the onset of the study, agreeing to adopt reliable contraceptive measures during the study * written informed consent signed exclusion criteria: * asc-h (atypical squamous cells, cannot exclude hsil) or hsil (high-grade squamous intraepithelial lesions) or agc (atypical glandular cells) or ais (adenocarcinoma in situ) on cytology, or malignant cells on cytology or histology, or other suspicion of either micro-invasive or invasive disease * invasive carcinoma possibility or lesions extending to the vaginal vault or suspicion of endocervical disease on colposcopy * severe pelvic inflammatory disease, severe cervicitis, or other severe gynaecological infection as per clinical examination * undiagnosed vaginal bleeding * with allergic disease at present; known or suspected porphyria; known allergy to ala or analogues * with serious cardiovascular, neurologic, psychiatric, endocrine, hematological disease; immunocompromised conditions; patients with malignant tumors * hepatic or renal functions abnormal (alanine aminotransferase or aspartate transaminase or total bilirubin \> 1.5 upper limit of normal \[uln\], or serum creatinine or blood urea nitrogen \> 1.5 uln) * pregnancy or nursing * previous physical therapy of lsil/cin1 after pathologic diagnosis * participation in any clinical studies within the last 30 days * subjects that the investigators judged to be not suitable to participate the study besides above
influence of two different peep niveaus and a trendelenburg positioning manoeuvre on subclavian vein diameter

Conditions: Insufficiency; Cardiac, Complicating Surgery

Summary: in 50 patients who are undergoing a planned surgical procedure which require a central venous catheter the diameter of the subclavian vein is measured by ultrasound under 6 different conditions.

in 50 patients who are undergoing a planned surgical procedure which require a central venous catheter the diameter of the subclavian vein is measured by ultrasound under 6 different conditions. the conditions are 1. neutral positioning, peep 0 cm h2o, 2. neutral positioning, peep 5cm h2o, 3. neutral positioning, peep 10cm h2o, 4. trendelenburg positioning -20°, peep 0 cmh2o, 5. trendelenburg positioning -20°, peep 5 cmh2o, 6. trendelenburg positioning -20°, peep 10 cmh2o after these measurements a central venous catheter is used to measure the central venous pressure.

Eligibility criteria:
inclusion criteria: * age \>18 years * cardiosurgery or neurosurgery * written informed consent * ecg: inus rhythm exclusion criteria: * peacemaker * kontraindications for peep * pulmonary disease * hemodynamically instable patients * pregnancy * pulmonal hypertension * ejection fraction \< 35% * severe valvular disease * tricuspid insufficiency

Keywords: ultrasound
study of the impact of time of vaccination on response to influenza vaccine in kidney transplant recipients -chronovax

Conditions: Vaccination; Infection

Summary: immune response to influenza vaccine in kidney transplant patients

seasonal influenza vaccination is recommended for kidney transplant patients, as influenza is responsible for significant morbidity and mortality in this immunocompromised population. nevertheless, injection of influenza vaccine induces a protective immune response in only 20% to 40% of patients. today, there are no recommendations regarding the injection time of influenza vaccine in the general population or in immunocompromised patients. in this context, recent studies conducted in healthy subjects have shown that the time of vaccination can have an impact on vaccine efficacy. this is the case for bcg, influenza, covid-19. on this basis, we formulate the main hypothesis that the administration of influenza vaccine to kidney transplant patients would be more effective when carried out in the morning than in the evening.

Eligibility criteria:
inclusion criteria: * renal transplant patient; * follow-up at nice university hospital; * age \> 18 years; * indication for influenza vaccination * free and informed consent; * immunosuppressive treatment including anti-calcineurin and/or mycophenolate mofetil (with or without corticoids). exclusion criteria: * known hypersensitivity to influenza vaccine or egg proteins; * influenza vaccination for the 2023-2024 season already performed; * current infection; * current acute medical condition; * treatment of rejection within the previous 3 months; * immunosuppressive therapy including ctla4 agonist, mtor inhibitor, complement inhibitor, anti-cd19; * polyvalent immunoglobulin infusion within the preceding 3 months; * vulnerable persons (minors, adults under guardianship or trusteeship, pregnant women, persons deprived of their liberty, persons unable to speak french); * subjects not affiliated to the social security system.

Keywords: influenza kidney transplant vaccination